

# VASCADE MVP<sup>®</sup>

Vascular Closure for EP Procedures

**Early Ambulation.  
Simple.  
Proven.**

Simple &  
Easy to Use

0% Major  
Complications in:  
1,223 Patients in  
5 EP Clinical  
Trials<sup>1-5</sup>




**Designed for EP Procedures.  
Proven by EPs.**

**HAEMONETICS<sup>®</sup>**

# Early Ambulation

## AMBULATE Clinical Trial<sup>1</sup>

Prospective, Multicentre Randomised 1:1 Clinical Trial



### Study Endpoints

**Primary Endpoints**  
Time to ambulation, major access site complications

**Additional Data**  
Patient satisfaction, use of pain medications


## 3.9 hour reduction in median time to ambulation

Time to Ambulation	Patient Satisfaction	Opioid Use
64% REDUCTION	63% IMPROVEMENT	58% REDUCTION
Reduction in Median Time to Ambulation	Improvement in Patient Satisfaction	Reduction in Opioid Use

Safety Endpoints	VASCADE MVP <sup>®</sup> n=199 limbs	Manual Compression n=209 limbs	P Value
Major Complications	0%	0%	–
Minor Complications	1.0%	2.4%	0.45 <sup>6</sup>

# Simple

## Designed for EP Procedures



### Extravascular design

- No permanent or intraluminal implants

### Bioabsorbable and thrombogenic collagen plug

- Expands to fill tissue tract

### 2 mechanisms of action

- Mechanical
- Physiological

### Simple and easy to use

- Single operator
- No sutures or material left in vessel

# Proven

## Proven by EPs in AMBULATE Clinical Trial<sup>1</sup> and AMBULATE Same Day Discharge Clinical Studies<sup>2-5</sup>

Prospective multicentre studies of same day discharge in paroxymal and persistent AF ablation patients

### Using the VASCADE MVP<sup>®</sup> Venous Vascular Closure System

Simple & Easy to Use  
0% Major Complications in: 1,223 Patients in 5 EP Clinical Trials<sup>1-5</sup>

1,106  Access Sites

354  Patients

45  Investigators

14  U.S. Centres

91.2%

Discharged the Same Day (SDD)

99.7%

SDD Success with no access site complications<sup>7</sup>

0%

ZERO (0) major complications<sup>8</sup>

# Ordering Information

PRODUCT	CATALOGUE NUMBER	DESCRIPTION	QUANTITY
VASCADE MVP® Venous Vascular Closure System (VVCS)	800-612C-10E	6–12F Inner Diameter (15F maximum outer diameter)	1 box (10 devices per box)

The VASCADE MVP Venous Vascular Closure System (VVCS) Model 800-612C is indicated for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to haemostasis, and time to discharge eligibility compared to manual compression, and enabling same day discharge in patients who have undergone catheter-based procedures using 6 – 12F inner diameter (15F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs.

Please consult product labels and instructions for use for indications, contraindications, warnings, precautions and adverse events. See VASCADE MVP® EU IFU 5686 Instructions for Use.

## Learn More:

Find your local contact

[www.haemonetics.com](http://www.haemonetics.com)

1. Natale A, et al. Venous vascular closure system versus manual compression following multiple access electrophysiology procedures: The AMBULATE Trial. *JACC Clin Electrophysiol* 2020; 6(1):111-124.
2. Al-Ahmad A, et al. Results from the prospective, multicenter AMBULATE-CAP trial: Reduced use of urinary catheters and protamine with hemostasis via the mid-bore venous vascular closure system VASCADE MVP following multi-access cardiac ablation procedures. *J Cardiovasc Electrophysiol* 2021. 32(2): 191-99.
3. AMBULATE Same Day Discharge Registry Retrospective Study: NCT04538781
- 4/5. Eldadah ZA, et al. Same-day discharge following catheter ablation and venous closure with VASCADE MVP: A post-market registry. Published online Nov 30, 2022. *J Cardiovasc Electrophysiol* <https://doi.org/10.1111/jce.15763>
6. P-values from 2-sided Wilcoxon rank-sum test for medians, unadjusted for stratification factor.
7. Venous access site closure-related complications through 15-day follow up
8. Major venous access site closure-related complications through 15-day follow up